Adicet Bio (ACET) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ACET Adicet Bio

Watchlist

0.910
+0.050+5.78%

Close Dec 20 16:00 ET

0.950
+0.040+4.40%

Post 20:01 ET

74.98MMarket Cap-0.54P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Analysts Have Conflicting Sentiments on These Healthcare Companies: Celldex (CLDX), Oruka Therapeutics (ORKA) and Adicet Bio (ACET)
TipRanksDec 20 12:51 ET · Ratings
H.C. Wainwright Remains a Hold on Adicet Bio (ACET)
TipRanksDec 20 12:50 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Neutral on Adicet Bioto Neutral
BenzingaDec 19 11:39 ET
Adicet Bio Says 1st Patient Dosed in Phase1 Trial of ADI-270 to Treat CcRCC
TipRanksDec 19 07:10 ET
Adicet Bio Says First Patient Dosed In The Phase 1 Clinical Trial Evaluating ADI-270 In Patients With Metastatic/Advanced CcRCC
BenzingaDec 19 07:09 ET
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
BusinesswireDec 19 07:00 ET

Comments

Stock_Drift

Dec 19 06:14

$Adicet Bio (ACET.US)$

Trytosaveabit

Nov 19 05:40

Watching to see if any surprises come from this?

$Adicet Bio (ACET.US)$ Adicet Bio To Present At Jefferies London Healthcare Conference; Webcast At 7:30 AM ET

Jaguar8

Nov 18 15:04

NEWS

$Adicet Bio (ACET.US)$
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Adicet Bio, Inc. has launched a Phase 1 clinical trial for ADI-270, targeting metastatic clear cell renal cell carcinoma, marking a significant step in utilizing gamma delta CAR T cell therapies for solid tumors.
The company also began dosing a lupus nephritis patient in a trial for ADI-001, highlighting its focus on autoimmune diseases.
Preliminary data f...

Jaguar8

Nov 16 16:44

My watchlist Monday. Why? +Data from CAR-T cell therapy

$Adicet Bio (ACET.US)$

Jaguar8

Nov 16 15:44

NEWS

$Adicet Bio (ACET.US)$
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
Adicet Bio (NASDAQ: ACET) presented clinical biomarker data for ADI-001, their off-the-shelf gamma delta CAR T cell therapy, at ACR Convergence 2024.
The data showed robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue, with CAR T cell activation levels of 27-64% at the 1E9 do...

Heat List

Overall

No Data